Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Of 4 Major Drug Wholesalers, Only Medipal to Increase Operating Profits in FY2011: Mizuho
July 25, 2011
- FDA Accepts Application for Dacogen for AML: Eisai
July 25, 2011
- Lyrica Shows Efficacy for Fibromyalgia in PIII in Japan: Pfizer
July 25, 2011
- NBI Expects Surge in Sales of Prazaxa after Lifting of Ban on Long-term Prescription
July 25, 2011
- Shionogi Licenses IPF Treatment Pirfenidone to Ildong of South Korea
July 25, 2011
- EPPV Finds No Safety-related Problems with Rasuritek: sanofi-aventis
July 25, 2011
- Lantus Plus One Mealtime Dose of Apidra Non-inferior to Insulin Aspart: Sanofi
July 25, 2011
- Eisai Obtains Marketing Rights to 2 Drugs from Orion in China
July 25, 2011
- Aricept Generics Approved from 33 Companies
July 25, 2011
- Novo Nordisk's Ultra-Long-Acting Insulin Reduces Incidence of Hypoglycemia
July 25, 2011
- Astellas to Market Pfizer's Caduet from October
July 25, 2011
- DSP to Launch Aricept Generics to Expand Product Lineup in CNS Field
July 25, 2011
- 4,000 Patients Registered with All-Case Survey on Orencia: Bristol-Myers
July 25, 2011
- Astellas Files Suit Against Sandoz Canada Over Generic Version of Prograf
July 25, 2011
- Nippon Chemiphar to Launch Generic Version of Aricept in Nov.
July 25, 2011
- Chugai to Take Safety Measures for Tarceva in Patients with Pancreatic Cancer
July 25, 2011
- Chugai to Fully Recommence Production at Utsunomiya Plant in August
July 25, 2011
- Nichi-Iko to Copromote Radicut Generic with sanofi-aventis
July 25, 2011
- Therapy Using Human Stem Cells to Be Covered by Health Insurance for First Time
July 25, 2011
- Drug Production in March Down as Much as 65% in 3 Quake-hit Prefectures: Korosho
July 25, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…